Finding: Supported conserved catalytic function; mitochondrial targeting is not assessed by this claim.
Target: A0A9L0TSN4, Equus caballus. The exact source is the frozen ProtNLM API response dated 2026-09-08, retained in projects/PROTNLM_EVALUATION/mammal-benchmark/predictions.jsonl.gz.
Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine
Supported. Human mitochondrial BCAT2 structural and kinetic work establishes transamination of branched-chain substrates (PMID:17050531). The horse protein aligns across the full human enzyme and preserves the mapped substrate-contact residues. The extra 60-residue N-terminal segment does not remove that catalytic domain.
Supported. The experimentally characterized human enzyme has the substrate spectrum given in the prediction. Its human UniProt functional statement is grounded in biochemical papers, including PMID:17050531 and PMID:25653144; mapped contacts and broad sequence conservation support transfer to this horse enzyme.
The statement is a plausible conserved mammalian enzyme function, not an equine-specific experimental observation. The selected model has a long N-terminal extension; this analysis does not certify mitochondrial targeting. The narrative adds a substrate-level description to target GOA branched-chain amino acid catabolism; training membership is unknown.
The reproducible paired sequence comparison records residue-level findings and sequence hashes. The human UniProt source distinguishes experimental supporting papers from inferred statements. ARBA assertions and generated review prose are not used as validating evidence.